Antisense Therapeutics (ASX:ANP)
ASX Junior’s Flagship Immunomodulatory Drug Could Turn the Tide in Duchenne Muscular Dystrophy Treatment
Oct 16, 2018
Duchenne muscular dystrophy (DMD) is a rare, yet fatal, muscular genetic condition that affects one in 3600 to 6000 male births worldwide. This ASX junior, capped at just $7 million, is already in a Phase II clinical trial with its flagship drug to treat DMD.